Back to top
more

Syndax Pharmaceuticals (SNDX)

(Delayed Data from NSDQ)

$23.28 USD

23.28
719,171

-0.11 (-0.47%)

Updated Jul 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ultragenyx (RARE) Posts Preliminary '22 Results, Gives '23 View

by Zacks Equity Research

Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.

Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results

by Zacks Equity Research

Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.

Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22

by Zacks Equity Research

Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.

FATE To End Janssen Deal and Prioritize Pipeline Development

by Zacks Equity Research

FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.

FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA

by Zacks Equity Research

The FDA's decision on AstraZeneca (AZN)/Sanofi's (SNY) regulatory filing, seeking approval for using their RSV antibody in all infants, is expected in third-quarter 2023.

Roche's (RHHBY) Cancer Drug Glofitamab Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts and grants priority review to Roche's (RHHBY) biologics license application for glofitamab to treat relapsed or refractory large B-cell lymphoma. The decision is due on Jul 1, 2023.

Geron (GERN) Up on Imetelstat Data on Myelodysplastic Syndromes

by Zacks Equity Research

Geron (GERN) posts positive top-line data from the phase III IMerge study investigating its lead candidate, imetelstat for treating lower risk myelodysplastic syndromes. Shares up.

Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA

by Zacks Equity Research

Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for treating erosive esophagitis.

VERA Dips Despite Positive Data From IgA Nephropathy Study

by Zacks Equity Research

VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.

Deciphera (DCPH) Issues Strategic & Corporate Outlook for 2023

by Zacks Equity Research

Deciphera (DCPH) provides a strategic outlook and planned corporate milestones for 2023. The company also posts preliminary fourth-quarter and 2022 revenues.

Wall Street Analysts Believe Syndax (SNDX) Could Rally 44%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Syndax (SNDX) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why Momentum in Syndax (SNDX) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Syndax (SNDX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

GSK's New Drugs and Pipeline Hold the Key to Growth in 2023

by Zacks Equity Research

GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.

Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout

by Zacks Equity Research

Axsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The Sunosi deal and promising pipeline bode well. Stiff competition in the target market remains a woe.

TG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug

by Zacks Equity Research

The FDA approves TG Therapeutics' (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch the drug in the first quarter of 2023. Stock up.

AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers

by Zacks Equity Research

The Japanese Ministry of Health approves AstraZeneca's (AZN) Imfinzi plus Imjudo for treating advanced liver cancer and lung cancer.

Kala Pharmaceuticals (KALA) Up as FDA Accepts IND for KPI-012

by Zacks Equity Research

The FDA accepts Kala Pharmaceuticals' (KALA) investigational new drug application for pipeline candidate KPI-012 for treating persistent corneal epithelial defect. Stock up.

ACER Down Despite FDA Nod for Urea Cycle Disorders Drug

by Zacks Equity Research

The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.

Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals

by Zacks Equity Research

Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article.

4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023

by Zacks Equity Research

New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR and SNDX well amid the volatility.

Sanofi's (SNY) Dupixent & Vaccines Make the Stock Attractive

by Zacks Equity Research

One can invest in Sanofi (SNY) due to the strong performance of Dupixent, above-market sales growth of the Consumer unit, consistent pipeline innovation and regular accretive collaboration deals.

Has scPharmaceuticals (SCPH) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how scPharmaceuticals, Inc. (SCPH) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.

Wall Street Analysts Predict a 45% Upside in Syndax (SNDX): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 44.7% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here's What Could Help Syndax (SNDX) Maintain Its Recent Price Strength

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Syndax (SNDX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement. Stock up.